80 related articles for article (PubMed ID: 24473897)
1. Quantitative assessment of in vivo HIV protease activity using genetically engineered QD-based FRET probes.
Cella LN; Biswas P; Yates MV; Mulchandani A; Chen W
Biotechnol Bioeng; 2014 Jun; 111(6):1082-7. PubMed ID: 24473897
[TBL] [Abstract][Full Text] [Related]
2. A quantum-dot based protein module for in vivo monitoring of protease activity through fluorescence resonance energy transfer.
Biswas P; Cella LN; Kang SH; Mulchandani A; Yates MV; Chen W
Chem Commun (Camb); 2011 May; 47(18):5259-61. PubMed ID: 21445447
[TBL] [Abstract][Full Text] [Related]
3. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors.
Kinomoto M; Appiah-Opong R; Brandful JA; Yokoyama M; Nii-Trebi N; Ugly-Kwame E; Sato H; Ofori-Adjei D; Kurata T; Barre-Sinoussi F; Sata T; Tokunaga K
Clin Infect Dis; 2005 Jul; 41(2):243-51. PubMed ID: 15983923
[TBL] [Abstract][Full Text] [Related]
5. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.
Palma AC; Covens K; Snoeck J; Vandamme AM; Camacho RJ; Van Laethem K
J Antimicrob Chemother; 2012 May; 67(5):1075-9. PubMed ID: 22331593
[TBL] [Abstract][Full Text] [Related]
7. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.
Shenderovich MD; Kagan RM; Heseltine PN; Ramnarayan K
Protein Sci; 2003 Aug; 12(8):1706-18. PubMed ID: 12876320
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
Côté HC; Brumme ZL; Harrigan PR
J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
[TBL] [Abstract][Full Text] [Related]
9. Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors.
Braz AS; Tufanetto P; Perahia D; Scott LP
Proteins; 2012 Dec; 80(12):2680-91. PubMed ID: 22821809
[TBL] [Abstract][Full Text] [Related]
10. Fluorogenic assay and live cell imaging of HIV-1 protease activity using acid-stable quantum dot-peptide complex.
Choi Y; Lee J; Kim K; Kim H; Sommer P; Song R
Chem Commun (Camb); 2010 Dec; 46(48):9146-8. PubMed ID: 21049123
[TBL] [Abstract][Full Text] [Related]
11. Visualization of human immunodeficiency virus protease inhibition using a novel Förster resonance energy transfer molecular probe.
Jin S; Ellis E; Veetil JV; Yao H; Ye K
Biotechnol Prog; 2011 Jul; 27(4):1107-14. PubMed ID: 21584951
[TBL] [Abstract][Full Text] [Related]
12. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
[TBL] [Abstract][Full Text] [Related]
13. Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development.
Beck ZQ; Hervio L; Dawson PE; Elder JH; Madison EL
Virology; 2000 Sep; 274(2):391-401. PubMed ID: 10964781
[TBL] [Abstract][Full Text] [Related]
14. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.
Wensing AM; van Maarseveen NM; Nijhuis M
Antiviral Res; 2010 Jan; 85(1):59-74. PubMed ID: 19853627
[TBL] [Abstract][Full Text] [Related]
15. Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
Naicker P; Achilonu I; Fanucchi S; Fernandes M; Ibrahim MA; Dirr HW; Soliman ME; Sayed Y
J Biomol Struct Dyn; 2013 Dec; 31(12):1370-80. PubMed ID: 23140382
[TBL] [Abstract][Full Text] [Related]
16. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
Weinheimer S; Discotto L; Friborg J; Yang H; Colonno R
Antimicrob Agents Chemother; 2005 Sep; 49(9):3816-24. PubMed ID: 16127058
[TBL] [Abstract][Full Text] [Related]
17. Resistance to protease inhibitors.
Kuritzkes DR
J HIV Ther; 2002 Nov; 7(4):87-91. PubMed ID: 12733606
[TBL] [Abstract][Full Text] [Related]
18. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
19. Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy.
Morand-Joubert L; Charpentier C; Poizat G; Chêne G; Dam E; Raguin G; Taburet AM; Girard PM; Hance AJ; Clavel F
Antivir Ther; 2006; 11(2):143-54. PubMed ID: 16640095
[TBL] [Abstract][Full Text] [Related]
20. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
Holguín A; Paxinos E; Hertogs K; Womac C; Soriano V
J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
